Cosmo Pharmaceuticals (COPN) Investor Day 2025 summary

Strategic vision and business transformation

• Announced a 2030 vision to become the most innovative force in life sciences, focusing on gut, skin, and AI-driven MedTech, with a €222B TAM and CAGRs up to 39%.

• Mission centers on empowering patients, professionals, and partners with life-changing confidence through science and technology, emphasizing gut, skin, and AI.

• Four business verticals: MedTechAI, dermatology, gastroenterology, and CDMO, streamlining structure for innovation and market leadership.

• Strategic partnerships with industry leaders like Medtronic, Takeda, Ferring, Sun, NVIDIA, and Apple to amplify scale and innovation.

• Divestment of non-core assets (solid tumors, digital trust) to focus on core areas and maximize clarity and growth.

Financial outlook and growth targets

• Targeting a 39% CAGR in recurring revenue, aiming to reach €480M by 2030, with EBITDA margin expanding from 19% to 40%.

• Recurring revenues expected to triple from $85–90M in 2024 to $260M by 2029, driven by existing portfolio and global expansion of Winlevi and GI Genius.

• New products, especially clascoterone solution for hair loss, projected to contribute 95% of late-stage revenue growth by 2030.

• Capital allocation remains disciplined, prioritizing R&D, strategic partnerships, and shareholder returns, with over $150M paid in dividends to date and above 4x return targeted.

• No debt and strong balance sheet provide flexibility for organic and inorganic growth, supported by significant cash position.

Key business developments and pipeline updates

• Winlevi is the #1 topical acne prescription in the U.S., expanding to 40 countries by 2027, representing an €8B opportunity.

• Clascoterone solution (Breezula) for androgenetic alopecia completed Phase 3 enrollment, with results expected in fall 2025 and commercialization post-2027 FDA approval.

• MedTechAI pipeline expanding globally, now in 28 countries and over 4M patients, with new modules and Apple Vision Pro integration.

• Digital health initiatives include AI-powered digital companions and telehealth channels, driving patient engagement and new recurring revenue streams.

• Pharma pipeline advancing in bile acid diarrhea and distal ulcerative colitis, with clinical trials ongoing and results expected in 2025.